Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile

You may also be interested in...

AstraZeneca Toprol Patents Are Invalid, Finds Federal Judge

A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.

Statin Safety Report Due Out At Year-End, National Lipid Assoc. Says

Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.

Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts